Email this article 
Disseminated medullary thyroid carcinoma. Optimal approach to treatment
- Authors: Romanov I.S.1, Dronova E.L.1, Stanyakina E.Е.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 8, No 4 (2018)
- Pages: 21-25
- Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
- Published: 13.12.2018
- URL: https://ogsh.abvpress.ru/jour/article/view/370
- DOI: https://doi.org/10.17650/2222-1468-2018-8-4-21-25
- ID: 370
Cite item
Full Text
Abstract
Medullary thyroid cancer is a rare tumor. Due to variability of its biological behavior, treatment of this tumor often is a complicated problem. Clinicians have difficulties with determination of indications for prescription of tyrosine kinase inhibitors. Prescription should be based on scru-tinous monitoring of the patients and consideration of all factors: level of tumor markers, patient’s state, and data form visual examinations.
About the authors
I. S. Romanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: drromanov@mail.ru
ORCID iD: 0000-0002-5421-5985
24 Kashirskoe Shosse, Moscow 115478
Russian FederationE. L. Dronova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-8404-0311
24 Kashirskoe Shosse, Moscow 115478
Russian FederationE. Е. Stanyakina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
ORCID iD: 0000-0002-0949-0320
24 Kashirskoe Shosse, Moscow 115478
Russian FederationReferences
- Wells S.A. Jr, Asa S.L., Dralle H. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567—610. doi: 10.1089/thy.2014.0335. PMID: 25810047.
- Sippel R.S., Kunnimalaiyaan M., Chen H. Current management of medullary thyroid cancer. Oncologist 2008;13 (5):539—47. doi: 10.1634/theoncologist.2007-0239. PMID: 18515739.
- Rumyantsev P.O., Ilyin A.A., Saenko V.A. Thyroid cancer: modern approaches to diagnosis and treatment. M.: Geotar-Media, 2009. 448 p. (In Russ.).
- Roman S., Lin R., Sosa J.A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107(9):2134—42. doi: 10.1002/cncr.22244. PMID: 17019736.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Thyroid carcinoma. Version 1.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
- Valerio L., Pieruzzi L., Giani C. et al. Targeted therapy in thyroid cancer: state of the art. Clin Oncol (R Coll Radiol) 2017;29(5):316—24. doi: 10.1016/j.clon.2017.02.009. PMID: 28318881.
- Wells S.A. Jr, Robinson B.G., Gagel R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134—41. doi: 10.1200/JCO.2011.35.5040. PMID: 22025146.
- Maciel L.M. Z., Magalhaes PK. R. Medullary thyroid carcinoma — adverse events during systemic treatment: risk-benefit ratio. Arch Endocrinol Metab 2017;61(4):398—402. doi: 10.1590/2359-3997000000267. PMID: 28658345.
Supplementary files
